Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
Julien Lagarde, Pauline Olivieri, Matteo Tonietto, Sébastian Rodrigo, Philippe Gervais, Fabien Caillé, Martin Moussion, Michel Bottlaender, Marie Sarazi. Could tau-PET imaging contribute to a better understanding of the different patterns of clinical progression in Alzheimer's disease? A 2-year longitudinal study. Alzheimer's research & therapy. vol 15. issue 1. 2023-05-03. PMID:37138309. |
monitoring the progression of tau pathology makes it possible to study the clinical diversity of alzheimer's disease. |
2023-05-03 |
2023-08-14 |
Not clear |
Andrea Arsiccio, Xikun Liu, Pritam Ganguly, Steven K Buratto, Michael T Bowers, Joan-Emma She. Effect of Cosolutes on the Aggregation of a Tau Fragment: A Combined Experimental and Simulation Approach. The journal of physical chemistry. B. 2023-05-02. PMID:37129599. |
the intrinsically disordered protein tau represents the main component of neurofibrillary tangles that are a hallmark of alzheimer's disease. |
2023-05-02 |
2023-08-14 |
Not clear |
Yingmei Tang, Minghui Cao, Yunhua Li, Yuting Lin, Xiaoyan Wu, Meiwei Che. Altered structural covariance of locus coeruleus in individuals with significant memory concern and patients with mild cognitive impairment. Cerebral cortex (New York, N.Y. : 1991). 2023-05-02. PMID:37130822. |
the locus coeruleus (lc) is the site where tau accumulation is preferentially observed pathologically in alzheimer's disease (ad) patients, but the changes in gray matter co-alteration patterns between the lc and the whole brain in the predementia phase of ad remain unclear. |
2023-05-02 |
2023-08-14 |
human |
Kumarappan Chidambara. Identification of BACE-1 Inhibitors against Alzheimer's Disease through E-Pharmacophore-Based Virtual Screening and Molecular Dynamics Simulation Studies: An Insilco Approach. Life (Basel, Switzerland). vol 13. issue 4. 2023-04-28. PMID:37109481. |
alzheimer is a severe memory and cognitive impairment neurodegenerative disease that is the most common cause of dementia worldwide and characterized by the pathological accumulation of tau protein and amyloid-beta peptides. |
2023-04-28 |
2023-08-14 |
Not clear |
Reem M Fars. The Role of Mitochondrial Dysfunction in Alzheimer's: Molecular Defects and Mitophagy-Enhancing Approaches. Life (Basel, Switzerland). vol 13. issue 4. 2023-04-28. PMID:37109499. |
alzheimer's disease (ad), a progressive and chronic neurodegenerative syndrome, is categorized by cognitive and memory damage caused by the aggregations of abnormal proteins, specifically including tau proteins and β-amyloid in brain tissue. |
2023-04-28 |
2023-08-14 |
Not clear |
Avinash H Bansode, Bhuvanachandra Bhoopal, Krishna Kumar Gollapelli, Naresh Damuka, Ivan Krizan, Mack Miller, Suzanne Craft, Akiva Mintz, Kiran Kumar Solingapuram Sa. Binding Parameters of [ Pharmaceuticals (Basel, Switzerland). vol 16. issue 4. 2023-04-28. PMID:37111252. |
binding parameters of [ impairment and/or destabilization of neuronal microtubules (mts) resulting from hyper-phosphorylation of the tau proteins is implicated in many pathologies, including alzheimer's disease (ad), parkinson's disease and other neurological disorders. |
2023-04-28 |
2023-08-14 |
Not clear |
Haishu Chen, Jinan Xu, Hanyuan Xu, Tiancheng Luo, Yihao Li, Ke Jiang, Yangping Shentu, Zhiqian Ton. New Insights into Alzheimer's Disease: Novel Pathogenesis, Drug Target and Delivery. Pharmaceutics. vol 15. issue 4. 2023-04-28. PMID:37111618. |
alzheimer's disease (ad), the most common type of dementia, is characterized by senile plaques composed of amyloid β protein (aβ) and neurofilament tangles derived from the hyperphosphorylation of tau protein. |
2023-04-28 |
2023-08-14 |
Not clear |
Musa O Iliyasu, Sunday A Musa, Sunday B Oladele, Abdullahi I Iliy. Amyloid-beta aggregation implicates multiple pathways in Alzheimer's disease: Understanding the mechanisms. Frontiers in neuroscience. vol 17. 2023-04-28. PMID:37113145. |
alzheimer's disease (ad) is a progressive neurodegenerative condition characterized by tau pathology and accumulations of neurofibrillary tangles (nfts) along with amyloid-beta (aβ). |
2023-04-28 |
2023-08-14 |
Not clear |
Hannah M Tayler, Robert MacLachlan, Özge Güzel, J Scott Miners, Seth Lov. Elevated late-life blood pressure may maintain brain oxygenation and slow amyloid-β accumulation at the expense of cerebral vascular damage. Brain communications. vol 5. issue 2. 2023-04-28. PMID:37113314. |
we have investigated the relationship of blood pressure and hypertensive status during late life (after 65 years) to post-mortem markers of alzheimer's disease (amyloid-β and tau loads); arteriolosclerosis and cerebral amyloid angiopathy; and to biochemical measures of ante-mortem cerebral oxygenation (the myelin-associated glycoprotein:proteolipid protein-1 ratio, which is reduced in chronically hypoperfused brain tissue, and the level of vascular endothelial growth factor-a, which is upregulated by tissue hypoxia); blood-brain barrier damage (indicated by an increase in parenchymal fibrinogen); and pericyte content (platelet-derived growth factor receptor β, which declines with pericyte loss), in alzheimer's disease ( |
2023-04-28 |
2023-08-14 |
Not clear |
Jasen F Saad, Fawzy A Saa. Gene Therapy for Alzheimer and Parkinson Diseases. Current gene therapy. 2023-04-28. PMID:37114789. |
β-amyloid peptides, α-synuclein, and tau aggregates start building up two decades before the onset of alzheimer and parkinson diseases. |
2023-04-28 |
2023-08-14 |
Not clear |
Nadia El Mammeri, Olivia Gampp, Pu Duan, Mei Hon. Membrane-induced tau amyloid fibrils. Communications biology. vol 6. issue 1. 2023-04-28. PMID:37117483. |
the intrinsically disordered protein tau aggregates into β-sheet amyloid fibrils that spread in human brains afflicted with alzheimer's disease and other neurodegenerative diseases. |
2023-04-28 |
2023-08-14 |
human |
Nicolas R Barthélemy, Benjamin Saef, Yan Li, Brian A Gordon, Yingxin He, Kanta Horie, Erik Stomrud, Gemma Salvadó, Shorena Janelidze, Chihiro Sato, Vitaliy Ovod, Rachel L Henson, Anne M Fagan, Tammie L S Benzinger, Chengjie Xiong, John C Morris, Oskar Hansson, Randall J Bateman, Suzanne E Schindle. CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer's disease. Nature aging. vol 3. issue 4. 2023-04-28. PMID:37117788. |
csf tau phosphorylation occupancies at t217 and t205 represent improved biomarkers of amyloid and tau pathology in alzheimer's disease. |
2023-04-28 |
2023-08-14 |
human |
Nicolas R Barthélemy, Benjamin Saef, Yan Li, Brian A Gordon, Yingxin He, Kanta Horie, Erik Stomrud, Gemma Salvadó, Shorena Janelidze, Chihiro Sato, Vitaliy Ovod, Rachel L Henson, Anne M Fagan, Tammie L S Benzinger, Chengjie Xiong, John C Morris, Oskar Hansson, Randall J Bateman, Suzanne E Schindle. CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer's disease. Nature aging. vol 3. issue 4. 2023-04-28. PMID:37117788. |
cerebrospinal fluid (csf) amyloid-β peptide (aβ)42/aβ40 and the concentration of tau phosphorylated at site 181 (p-tau181) are well-established biomarkers of alzheimer's disease (ad). |
2023-04-28 |
2023-08-14 |
human |
Petr Novak, Branislav Kovacech, Stanislav Katina, Reinhold Schmidt, Philip Scheltens, Eva Kontsekova, Stefan Ropele, Lubica Fialova, Milica Kramberger, Natalia Paulenka-Ivanovova, Miroslav Smisek, Jozef Hanes, Eva Stevens, Andrej Kovac, Stanislav Sutovsky, Vojtech Parrak, Peter Koson, Michal Prcina, Jaroslav Galba, Martin Cente, Tomas Hromadka, Peter Filipcik, Juraj Piestansky, Maria Samcova, Carmen Prenn-Gologranc, Roman Sivak, Lutz Froelich, Michal Fresser, Martin Rakusa, John Harrison, Jakub Hort, Markus Otto, Duygu Tosun, Matej Ondrus, Bengt Winblad, Michal Novak, Norbert Zilk. ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. Nature aging. vol 1. issue 6. 2023-04-28. PMID:37117834. |
adamant: a placebo-controlled randomized phase 2 study of aadvac1, an active immunotherapy against pathological tau in alzheimer's disease. |
2023-04-28 |
2023-08-14 |
Not clear |
Petr Novak, Branislav Kovacech, Stanislav Katina, Reinhold Schmidt, Philip Scheltens, Eva Kontsekova, Stefan Ropele, Lubica Fialova, Milica Kramberger, Natalia Paulenka-Ivanovova, Miroslav Smisek, Jozef Hanes, Eva Stevens, Andrej Kovac, Stanislav Sutovsky, Vojtech Parrak, Peter Koson, Michal Prcina, Jaroslav Galba, Martin Cente, Tomas Hromadka, Peter Filipcik, Juraj Piestansky, Maria Samcova, Carmen Prenn-Gologranc, Roman Sivak, Lutz Froelich, Michal Fresser, Martin Rakusa, John Harrison, Jakub Hort, Markus Otto, Duygu Tosun, Matej Ondrus, Bengt Winblad, Michal Novak, Norbert Zilk. ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. Nature aging. vol 1. issue 6. 2023-04-28. PMID:37117834. |
alzheimer's disease (ad) pathology is partly characterized by accumulation of aberrant forms of tau protein. |
2023-04-28 |
2023-08-14 |
Not clear |
Nader Morshed, Meelim J Lee, Felicia H Rodriguez, Douglas A Lauffenburger, Diego Mastroeni, Forest M Whit. Quantitative phosphoproteomics uncovers dysregulated kinase networks in Alzheimer's disease. Nature aging. vol 1. issue 6. 2023-04-28. PMID:37117831. |
alzheimer's disease (ad) is a form of dementia characterized by amyloid-β plaques and tau neurofibrillary tangles that progressively disrupt neural circuits in the brain. |
2023-04-28 |
2023-08-14 |
Not clear |
Joana B Pereira, Shorena Janelidze, Olof Strandberg, Christopher D Whelan, Henrik Zetterberg, Kaj Blennow, Sebastian Palmqvist, Erik Stomrud, Niklas Mattsson-Carlgren, Oskar Hansso. Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer's disease pathology. Nature aging. vol 2. issue 12. 2023-04-28. PMID:37118533. |
microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying alzheimer's disease pathology. |
2023-04-28 |
2023-08-14 |
Not clear |
Joana B Pereira, Shorena Janelidze, Olof Strandberg, Christopher D Whelan, Henrik Zetterberg, Kaj Blennow, Sebastian Palmqvist, Erik Stomrud, Niklas Mattsson-Carlgren, Oskar Hansso. Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer's disease pathology. Nature aging. vol 2. issue 12. 2023-04-28. PMID:37118533. |
the role of microglia in tau accumulation is currently unclear but could provide an important insight into the mechanisms underlying alzheimer's disease (ad) |
2023-04-28 |
2023-08-14 |
Not clear |
Luying Qiao, Yang Shen, Guangzhi Li, Guanglei Lv, Chunxia L. Hypochlorous Acid-Activated UCNPs-LMB/VQIVYK Multifunctional Nanosystem for Alzheimer's Disease Treatment. Journal of functional biomaterials. vol 14. issue 4. 2023-04-27. PMID:37103297. |
the development of nanosystems, which can photooxygenate amyloid-β (aβ), detect the tau protein, and inhibit effectively the tau aggregation, is increasingly important in the diagnosis and therapy of alzheimer's disease (ad). |
2023-04-27 |
2023-08-14 |
Not clear |
Seyed Hani Hojjati, Tracy A Butler, Gloria C Chiang, Christian Habeck, Arindam RoyChoudhury, Farnia Feiz, Jacob Shteingart, Siddharth Nayak, Sindy Ozoria, Antonio Fernández, Yaakov Stern, José A Luchsinger, Davangere P Devanand, Qolamreza R Razligh. Distinct and joint effects of low and high levels of Aβ and tau deposition on cortical thickness. NeuroImage. Clinical. vol 38. 2023-04-27. PMID:37104927. |
alzheimer's disease (ad) is defined by the presence of amyloid-β (aβ),tau, and neurodegeneration (atn framework) in the human cerebral cortex. |
2023-04-27 |
2023-08-14 |
human |